Edgewise Therapeutics
EWTX
200 hedge funds and large institutions have $2.64B invested in Edgewise Therapeutics in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 71 increasing their positions, 63 reducing their positions, and 20 closing their positions.
137% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $9.81M
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
13% more funds holding
Funds holding: 177 → 200 (+23)
13% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 63
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2% less capital invested
Capital invested by funds: $2.71B → $2.64B (-$63.4M)
3.56% less ownership
Funds ownership: 108.11% → 104.55% (-3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$54.3M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$24.9M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$17.5M |
| 4 |
Janus Henderson Group
London,
|
+$13.5M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$56.4M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$49.7M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$33.4M |
| 4 |
VA
VR Adviser
New York
|
-$26.7M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$17.5M |
EWTX Hedge Fund Activity: Q4 2024 in Review
200 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q4 2024, worth a combined $2.64B — down 2.3% from $2.71B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new EWTX positions and 20 closed out — a net gain of 24 holders — while 71 added to existing stakes and 63 trimmed.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $54.3M. The largest seller was TCG Crossover Management, exiting entirely with an estimated $56.4M sold.
- 200 institutional investors held Edgewise Therapeutics (EWTX) as of Q4 2024, up from 177 in Q3 2024.
- Funds reported $2.64B of Edgewise Therapeutics stock for Q4 2024, down 2.3% quarter-over-quarter.
- 44 funds opened new Edgewise Therapeutics positions in Q4 2024 and 20 closed out, a net change of +24 holders.
- The largest Edgewise Therapeutics buyer in Q4 2024 was Paradigm Biocapital Advisors, an estimated $54.3M added.
- The largest Edgewise Therapeutics seller in Q4 2024 was TCG Crossover Management, an estimated $56.4M sold.
Based on aggregated 13F filings for Q4 2024.